⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLLS News
Cellectis S.A. American Depositary Shares
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
globenewswire.com
CLLS
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
globenewswire.com
CLLS
Cellectis Announces Participation in Upcoming Investor Conferences
globenewswire.com
CLLS
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
prnewswire.com
CLLS
AUTL
FATE
GILD
NVS
Cellectis Reports Financial Results for the Second Quarter 2026
globenewswire.com
CLLS
Cellectis Reports Financial Results for the Second Quarter 2026
globenewswire.com
CLLS
Cellectis to Report Second Quarter Financial Results on August 6, 2026
globenewswire.com
CLLS
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
globenewswire.com
MGX
CLLS
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
globenewswire.com
CLLS
Celltaxis Names Co-Founder Eileen Heffernan as CEO to Accelerate Growth and Expand Leadership in Lymphatic Disease Therapeutics
prnewswire.com
CLLS